Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
Panelists discuss how stakeholders can enhance biosimilar uptake through coordinated efforts in financial alignment, patient-centric pricing, professional education, simplified administrative processes, and collaborative data exchange.
EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability
EP: 2.The Economic Impact of Biosimilars
EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars
EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars
EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption
EP: 6.Positioning Biosimilars in Clinical Practice
EP: 7.Assessing Patient Confidence With Biosimilars
Now Viewing
EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
EP: 9.The Growing Market for Biosimilars
EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models
EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies
EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability
EP: 13.How the IRA is Reshaping Biosimilar Adoption
EP: 14.Cost Savings Potential Associated With the Use of Biosimilars
EP: 15.Examining the Role of Interchangeability in Clinical Practice
EP: 16.Optimizing the Implementation of Biosimilars Into Formularies
EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars
EP: 18.Working With Policy Makers to Effectively Implement Biosimilars
Video content above is prompted by the following:
- How can different stakeholders such as providers, health systems, insurance providers, and pharmacy benefit managers work together more efficiently to optimize the uptake of biosimilars?
Related Videos
Related Content
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Article
Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More
